PMID- 10629412 OWN - NLM STAT- MEDLINE DCOM- 20000225 LR - 20171101 IS - 0301-0147 (Print) IS - 0301-0147 (Linking) VI - 29 Suppl S1 DP - 1999 Dec TI - Can all patients with deep vein thrombosis receive low-molecular-weight heparin in an outpatient setting? PG - 84-8 AB - Studies have shown subcutaneous low- molecular-weight heparin (LMWH) to be at least as safe and efficacious as intravenous unfractionated heparin (UFH) for the treatment of venous thromboembolism (VTE). Furthermore, unlike UFH, LMWH is administered on a once- or twice-daily basis without monitoring in uncomplicated cases. Consequently, it has been suggested that the large majority of patients with VTE could be treated on an outpatient basis. Exceptions include patients with an increased risk of haemorrhage, pregnant women, children and those with renal insufficiency. Outpatient management would offer economic advantages and be more convenient for both the patient and the hospital staff. CI - Copyright 1999 S. Karger AG, Basel FAU - Lindmarker, P AU - Lindmarker P AD - Coagulation Unit, Division of Haematology, Karolinska Hospital, Stockholm, Sweden. LA - eng PT - Journal Article PL - Switzerland TA - Haemostasis JT - Haemostasis JID - 0371574 RN - 0 (Anticoagulants) RN - 0 (Heparin, Low-Molecular-Weight) RN - 9005-49-6 (Heparin) SB - IM MH - Adolescent MH - Adult MH - Anticoagulants/adverse effects/*therapeutic use MH - Child MH - Child, Preschool MH - Female MH - Heparin/adverse effects/*therapeutic use MH - Heparin, Low-Molecular-Weight/adverse effects/*therapeutic use MH - Humans MH - Male MH - Outpatients MH - Pregnancy MH - Thrombophlebitis/*drug therapy/physiopathology EDAT- 2000/01/12 09:00 MHDA- 2000/03/04 09:00 CRDT- 2000/01/12 09:00 PHST- 2000/01/12 09:00 [pubmed] PHST- 2000/03/04 09:00 [medline] PHST- 2000/01/12 09:00 [entrez] AID - 54120 [pii] AID - 10.1159/000054120 [doi] PST - ppublish SO - Haemostasis. 1999 Dec;29 Suppl S1:84-8. doi: 10.1159/000054120.